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Among all the main problems of haemostasis, we can cite the 
discovery of novel anticoagulants without side effects. Ever since the 
discovery of the anticoagulant properties of hirudin from the leech 
saliva, the increasing relevance of thromboembolic diseases has 
encouraged a continuous search for new compounds with anticoagulant 
available anticoagulants [1]. One of the targets for prophylaxis and 
treatment of thromboembolic diseases is the plasma anticoagulant 
antithrombin. This protein circulates in blood in a metastable 
conformation, in which the reactive centre loop is partially inserted and 
is only activated by heparin and heparan sulfate glycosaminoglycans on 
the injured subendothelium [2]. Accordingly sulfated polysaccharide 
heparin chains with different size, from unfractionated to the 
essential pentasaccharide, have been used with more or less success in 
anticoagulant therapy and thromboprophilaxis [3]. In the last decades 
new molecules able to bind antithrombin have been identified. The 
strategies used in this search have been based mainly on the synthesis 
or chemical modification of existing drugs, or in the application of 
natural compounds with similar properties to those currently used [2]. 
Examples for such compounds are lignins and flavonoids [1,4], highly 
sulfated small organic ligands that seem to have similar properties to 
heparins.
Therefore, the discovery of novel or improved drugs for given 
diseases or special groups of patients, is a very slow and expensive 
process. Nevertheless, recent results demonstrate the discovery using 
Virtual Screening (VS) of a novel molecular scaffold [5], different to 
the previous ones based on heparin. Using this alternate approach, 
a large database of millions of chemical compounds is screened in-
silico and affinity-ranking is used to identify some at least weakly-
approach to tap into the wealth of available structural information [8,9]. 
Consequently, novel and enhanced VS methodologies, conveniently 
exploited in innovative drug discovery strategies can lead to significant 
and quantifiable developments.
An example of research group that performs drug design and 
discovery in this direction is the “Bioinformatics and High Performance 
Computing Research Group (BIO- HPC)”, as stated on their website 
(http://bio-hpc.eu). This research group works in many different but 
completely related research areas such as:
a) High Performance computing: their research interest includes 
massively parallel architectures such as Graphics Processing Units, 
Intel Xeon Phi and Heterogenous processors, as well as bio-inspired 
newest frontiers of computing. We are also working in applying 
these techniques to challenging problems in the fields of Science and 
Engineering [11,12].
b) Prediction studies of the biological activity of chemical substances 
by QSAR methods: their work is mainly focused on the search for 
structural alerts [13,14] for mutagenicity especially less studied for two 
trials (trials in mammalian cells and in vivo micronucleus studies) but 
also accepted by the OECD (Organization for Economic Cooperation 
and Development) for classification of mutagenicity of chemicals. They 
are also working with several universities to develop predictive QSAR 
models for different activities (study of antioxidant activity [15] and 
inhibition of human monoamine oxidase [16]). During this work they 
also make their contribution to the development of QSAR methodology 
[17]. 
c) Advanced Data Clustering Methods: Among the most relevant 
techniques used for pattern recognition, they develop and apply fuzzy 
clustering algorithms. These algorithms do not rely on assumptions 
common to conventional statistical methods, using the theory of fuzzy 
set. In the literature of fuzzy clustering, the fuzzy c-means (FCM) 
clustering algorithms defined by Dunn [18] and generated by Bezdek 
[19] are the well-known methods in cluster analysis. Recently Antonio 
et al. [20] and Soto et al. [21,22] showed modifications of FCM that 
improving probabilities in a fuzzy clustering partition. Currently, they 
are developing their own algorithms for applications in drug discovery, 
and big data, using HPC. 
d) Development and application of Computational Intelligence 
Methods: Virtual Screening (VS) methods can considerably aid clinical 
research, predicting how ligands interact with drug targets. However, 
the accuracy of most VS methods is constrained by limitations in the 
scoring function that describes biomolecular interactions, and even 
nowadays these uncertainties are not completely understood. In order 
to improve accuracy of scoring functions used in most VS methods 
they propose [23-25] a hybrid novel approach where neural networks 
(NNET) and support vector machines (SVM) methods are trained 
with databases of known active (drugs) and inactive compounds, this 
information being exploited afterwards to improve VS predictions. 
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activity, which has led to the development of the new commercially 
binding molecules for further refinement. Aided by ever-increasing 
computational power [3,6,7], VS is an appealing and cost-effective 
algorithms such as Ant Colony Optimization [10], to evaluate the 
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e) Biophysics of Ion Channels: Many physiological properties of 
undifferentiated mouse embryonic stem cells (mESCs), such as ion 
channel function, are not fully understood. Ion channels are thought to 
be involved in cell proliferation and to play an important role in mESCs 
differentiation. The aim of their study is to characterize functional ion 
channels [26,27] in cultured undifferentiated mESCs and their role 
in cell proliferation and differentiation, and apply obtained results to 
applied projects in drug discovery. 
Thus, we consider that in order to make efficient progress in drug 
discovery areas, a multidisciplinary research group, such as the one 
described in the previous paragraphs is necessary, and that research 
groups whose research line(s) are strictly focused on much concreted 
research areas cannot efficiently contribute to the development of the 
drug research field.
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